Viral Entry Denied

Publisher Website
Google Scholar
Abstract
Until recently, antiviral drugs were both uncommon and not terribly potent. This has changed: during the past decade, more than 30 antiviral drugs have been licensed, and many of them are very effective. Most of the drugs inhibit the activity of viral enzymes, but a new class of agents that block entry of the virus into the cell is being developed. The development of entry inhibitors is driven by the identification of the cell-surface receptors to which viruses bind and by new findings about viral protein structures that bind receptors and mediate viral entry. These advances offer exciting opportunities for . . .